Merck & Co Inc
MRK
Get informed when a big investor buys or sells
+ FollowEarnings Call Q1 2026
April 30, 2026 - AI Summary
Exclusive for Stockcircle Pro members
Sign up
Current Fair Value
11.9% upsideUndervalued by 11.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $293.22 Billion |
|---|---|
| Enterprise Value | $340.95 Billion |
| Dividend Yield | $3.32 (2.80%) |
| Earnings per Share | $7.3 |
| Beta | 0.2 |
| Outstanding Shares | 2,472,015,000 |
Return
| Return on Equity | 19.48% |
|---|---|
| Return on Assets | 6.94% |
| Return on Invested Capital | 15.50% |
Valuation & Multiples
| P/E Ratio | 32.85 |
|---|---|
| PEG | -17.9 |
| Price to Sales | 4.42 |
| Price to Book Ratio | 6.38 |
| Enterprise Value to Revenue | 5.18 |
| Enterprise Value to EBIT | 21.62 |
| Enterprise Value to Net Income | 38 |
| Total Debt to Enterprise | 0.16 |
| Debt to Equity | 1.16 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.8192▲ 11.81% |
|---|---|
| Total Calls | 24,390,216▼ 21.52% |
| Total Puts | 19,979,468▼ 8.30% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 76.90%▼ 2.07% |
|---|---|
| Total Invested | $231.37B▲ 11.76% |
| Investors Holding | 3,848▲ 114.00% |
ESG Score
No data
About Merck & Co Inc
CEO: Kenneth Frazier Relevant Senate Committees
Provides critical revenue estimates and analysis for all tax legislation, directly influencing corporate tax structures and fiscal policy development that impacts Merck's profitability.
Controls taxation, trade, and entitlement spending; directly impacts corporate tax rates, trade agreements, and crucially, Medicare pricing and reimbursement for pharmaceuticals.
Allocates discretionary federal spending, directly determining funding for NIH research, VA healthcare, and other government purchases of pharmaceuticals, impacting Merck's revenue streams.
Directly regulates the FDA, which approves pharmaceutical products and manufacturing standards, and influences NIH funding for crucial medical research.
Oversees antitrust laws and intellectual property; patent protection is fundamental to pharmaceutical R&D and profitability, and antitrust actions can impact mergers and market access.